9 results
To test the non-inferiority of the Synergy* abluminal coated everolimus eluting stent with bio-absorbable polymer from Boston Scientific compared to the Nobori* abluminal coated biolimus eluting stent with bio-absorbable polymer from Terumo in the…
The main objective of the present study is to investigate whether the ORSIRO coronary stent is non-inferior compared to the Xience coronary stent in patients with total coronary occlusions.
Inhibition of CYP2D6 enzymes by SSRIs may lead to reduced endoxifen plasma concentrations and thereby possibly influence tamoxifen treatment outcome. Paroxetine is a potent CYP2D6 inhibitor and strongly reduces endoxifen plasma concentrations.…
The objective of the ABSORB PHYSIOLOGY is to evaluate the following in participants undergoing coronary artery scaffolding/stenting for significant coronary artery disease:• The acute (post-implantation) effect of an implanted BVS or mDES on…
The primary objective of this study is to evaluate the effects of a CYP2D6 inhibitor, paroxetine, on the pharmacokinetics of a single dose of orally administered paliperidone ER. The safety and tolerability of the 3 mg tablet of paliperidone ER…
Primary Objective: The main objective is to compare the effectiveness and cost-effectiveness of Cognitive Behavioural Therapy (CBT) to psychopharmacological treatment with paroxetine in patients with Posttraumatic stress disorder (PTSD) in a…
Primary objective:To show that concomitant use of telaprevir (1125 mg BID) does not lead to a relevant decrease (> 20%) in the paroxetine parameter AUC0-24h compared to paroxetine alone.Secondary objectives:To determine the ratio of the…
This protocol will compare clinical outcomes of the SUPRAFLEX and XIENCE drug-eluting stents in a broad patient and lesion population and will gain substantial additional information on patients in a real world setting. These data will also provide…
TEMPO will directly compare i) conventional 2-step reduction with ii) gradual tapering in patients with remitted MDD who use either the antidepressant paroxetine (PAR) or venlafaxine (VLX). We will evaluate the number of patients that can…